SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from BNB PLUS CORP. (BNBX) (CIK 0000744452) (BNBX) — Nov 5, 2019

BNB PLUS CORP. (BNBX) (CIK 0000744452)
Date: Nov. 5, 2019 · CIK: 0000744452 · Accession: 0001104659-19-060127

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-233830

Date
November 5, 2019
Author
MAXIM GROUP LLC
Form
CORRESP
Company
BNB PLUS CORP. (BNBX) (CIK 0000744452)

Letter

Re: Applied DNA Sciences, Inc. (the “Company”)

Maxim Group LLC

November 5, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1, as amended

File Number: 333-233830

Ladies and Gentlemen:

Pursuant to Section 8(a) of the Securities Act of 1933, as amended, and Rule 461 promulgated thereunder, the undersigned, as the representative of the underwriters for the above-captioned proposed offering, join the acceleration request of the Company and hereby request acceleration of the effective date of the above-captioned Registration Statement to 5:00 p.m., Eastern Time, on November 7, 2019, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

(i) Date of preliminary prospectus: November 1, 2019

(ii) Dates of distribution: November 4, 2019 through the date hereof.

(iii) Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 12.

(iv) Number of prospectuses so distributed: 195.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating underwriters and dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Sincerely,
MAXIM GROUP LLC

Show Raw Text
CORRESP
1
filename1.htm

Maxim Group LLC

November 5, 2019

VIA EDGAR

        Securities and Exchange Commission

        Division of Corporation Finance

        100 F Street, N.E.

        Washington, D.C. 20549

 Re: Applied DNA Sciences, Inc. (the “Company”)

Registration Statement on Form S-1, as amended

File Number: 333-233830

Ladies and Gentlemen:

Pursuant to Section 8(a) of the Securities
Act of 1933, as amended, and Rule 461 promulgated thereunder, the undersigned, as the representative of the underwriters for the
above-captioned proposed offering, join the acceleration request of the Company and hereby request acceleration of the effective
date of the above-captioned Registration Statement to 5:00 p.m., Eastern Time, on November 7, 2019, or as soon thereafter as practicable.

The following is supplemental information
supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

 (i) Date of preliminary prospectus: November 1, 2019

 (ii) Dates of distribution: November 4, 2019 through the
date hereof.

 (iii) Number of prospective underwriters and selected dealers
to whom the preliminary prospectus was furnished: 12.

 (iv) Number of prospectuses so distributed: 195.

The
undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed
by participating underwriters and dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the
Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

    Sincerely,

    MAXIM GROUP LLC

    By:
    /s/ Clifford Teller

    Name:
    Clifford Teller

    Title:
    Executive Managing Director,

    Head of Investment Banking